Myovant Sciences (NYSE:MYOV) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Wednesday.
According to Zacks, “Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders, including advanced prostate cancer. The company’s product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda. “
Several other equities analysts have also commented on MYOV. ValuEngine upgraded shares of Myovant Sciences from a “sell” rating to a “hold” rating in a research note on Wednesday, April 4th. Barclays lowered shares of Myovant Sciences from an “overweight” rating to an “equal weight” rating and set a $18.00 price target on the stock. in a research note on Thursday, April 5th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $21.00.
MYOV stock opened at $20.73 on Wednesday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 5.04 and a current ratio of 5.04. Myovant Sciences has a fifty-two week low of $9.92 and a fifty-two week high of $24.14. The company has a market cap of $1,332.62, a P/E ratio of -12.19 and a beta of -2.44.
Myovant Sciences (NYSE:MYOV) last released its earnings results on Tuesday, February 13th. The company reported ($0.70) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.42) by ($0.28). analysts anticipate that Myovant Sciences will post -2.35 EPS for the current year.
In other news, major shareholder Pharmaceuticals Interna Takeda acquired 7,420,625 shares of the firm’s stock in a transaction dated Monday, March 19th. The stock was acquired at an average cost of $18.67 per share, with a total value of $138,543,068.75. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Holdings Ltd. Dexxon acquired 1,110,015 shares of the firm’s stock in a transaction dated Monday, April 2nd. The stock was purchased at an average cost of $20.27 per share, with a total value of $22,500,004.05. The disclosure for this purchase can be found here. Corporate insiders own 3.00% of the company’s stock.
Several hedge funds have recently bought and sold shares of MYOV. Point72 Asset Management L.P. acquired a new stake in shares of Myovant Sciences in the third quarter valued at approximately $1,255,000. Ardsley Advisory Partners acquired a new stake in shares of Myovant Sciences in the fourth quarter valued at approximately $1,272,000. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Myovant Sciences by 18.4% in the third quarter. JPMorgan Chase & Co. now owns 91,213 shares of the company’s stock valued at $1,382,000 after acquiring an additional 14,203 shares during the period. 81.44% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Myovant Sciences (MYOV) Stock Rating Upgraded by Zacks Investment Research” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/04/20/myovant-sciences-myov-stock-rating-upgraded-by-zacks-investment-research-2.html.
About Myovant Sciences
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.
Get a free copy of the Zacks research report on Myovant Sciences (MYOV)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.